Expression And Characterization Of Recombinant Hepatitis B Surface L Protein Antigen And Human IgG1Fc Fusion Protein

Infection with the hepatitis B virus is one of the most common infectious disease.Two thirds of chronically HBV-infected subjects develope liver cirrhosi -s,which is associated with high rate of mortality due to the development of hepatocel -lular carcinoma.Now,vaccination is the major way to prevent and control HBV. There is a comparably high rate of non-responders to present vaccine which contain only one antigen:the S antigen. Therapeutic approaches to control chronic hepatitis such as interferon-alpha and lamivudine are unsatisfactory. So therapeutic vaccines would be a powerful way with the lowest cost and the potentially greatest benefit.Thus,a new hepatitis B vaccine containing preSl,preS2,and S antigenic components has been developed to improve immune response against HBV. Recombination vector p3.1/rLHBs-Fc are constructed by inserting genes into pcDNA3.1,which modulate HBsAg presentation and enhance immune responses. Bioactive Results: (1) every epitope have antigenicity. (2) western blot of HRP- goat-anti-human IgGl(H+L) antibody reveal IgGlFc of fusion protein(3)the mice immunized with the HBsAg L paticles efficiently produce the anti-S,and anti-preS2 antibodies.Conclusion:rLHBs-Fc fusion protein has antigenicity and immunogenicity.